Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein and a glutamate-preferring carboxypeptidase with roles in folic acid utilization and metabolism encoded by FOLH1 in humans.1,2 It is composed of a short intracellular domain, a transmembrane domain, and a large extracellular region that contains enzymatic domains.1,3 PSMA is expressed in prostate epithelial cells and is highly overexpressed in prostate carcinomas. PSMA is also expressed in the central nervous system, where it metabolizes N-acetyl-aspartyl-glutamate, and in the proximal small intestine, where it functions as a carboxypeptidase and a folate hydrolase, as well as in the neovasculature of various renal, colon, and breast carcinomas.2,4 Expression of FOLH1 increases under androgen deprivation conditions in vitro and in vivo and positively correlates with cancer aggressiveness in patients with prostate cancer.1 PSMA positron emission tomography (PET) imaging is commonly used in the diagnosis and staging of prostate cancer, as well as to assess therapeutic response.3 Cayman’s PSMA (C-Term) Rabbit Monoclonal Antibody (Clone RM327) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
WARNING This product is not for human or veterinary use.
1. Overview of prostate-
2. Heterogeneity of prostate-
3. Nonprostatic diseases on PSMA PET imaging: A spectrum of benign and malignant findings. Cancer Imaging 20(1), 23 (2020).
4. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 91(3), 528-239 (2004).